Elligo Health Research is partnering with Saama Technologies to improve awareness of, access to, and participation in clinical trials for U.S. physicians and patients.
“We are excited to work with Saama to develop an innovative technology platform to transform the clinical research process overall, from standards-based data collection to eSubmissions to regulatory agencies,” said John Potthoff, Ph.D., Elligo CEO.
Through its Goes Direct model, Elligo engages physicians and their patients by first identifying patients using electronic health records and then providing their physicians with the infrastructure to conduct the research in their own offices at no cost to them. Saama’s Life Science Analytics Cloud, powered by its unique, AI-enabled Fluid Analytics Engine, includes the Cohort Builder and Trial Planning Optimizer solutions, which facilitate the identification of patient populations based on clinical trial eligibility requirements.
“Saama and Elligo have each pioneered innovative solutions that positively disrupt and improve the clinical trial landscape,” said Suresh Katta, founder and CEO of Saama. “Together, Saama and Elligo will set a new bar for physician and patient access to, and engagement with, clinical research that may improve patients’ health, enhance physicians’ understanding of disease management, and expand medical knowledge for treating some of the most prevalent and devastating human diseases.”